Subscribe to Updates

    Get the latest creative news from eReadIT about money, health, lifestyle and more.

    loader

    Email Address*

    Name

    Facebook X (Twitter) Instagram
    Trending
    • Alcaraz shakes off thigh injury to reach championship match at ATP Finals
    • Canadiens defenceman David Reinbacher draws in against Flyers
    • Nick Cousins returning to Senators lineup against Kings
    • Crazy line brawl breaks out between Michigan and Michigan State
    • Maple Leafs scratch Oliver Ekman-Larsson against Blue Jackets
    • Canucks place Gallagher on IR, recall Mueller, Quillan, Tolopilo from AHL
    • ‘No ill will’: Senators’ Cousins after big hit from Capitals’ Chychrun
    • Homan displays nice touch on clutch draw for two vs. Wrana
    EREADIT
    Write for Us
    • Write for Us
    • Local News
    • World
    • Politics
    • Money
    • Crypto
    • Technology
    • Sports
    • Entertainment
    • Game
    • Health
    • Lifestyle
    • Watch
    • Travel
    • Podcasts
    EREADIT
    Home»Health»Why stopping SSRIs can cause anxiety: A rebound in serotonin neuron activity may play a role
    Health

    Why stopping SSRIs can cause anxiety: A rebound in serotonin neuron activity may play a role

    BY Vladimir Hedrih November 21, 2026No Comments0 Views
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

     ​

    A study of male mice found that stopping treatment with the SSRI antidepressant paroxetine was associated with increased activity in two brain areas involved in anxiety, the dorsal raphe nucleus and the ventral hippocampus. These changes appeared two days after treatment ended, when the mice also showed elevated anxiety-like behavior. Five days after discontinuation, the anxiety-like behavior had subsided, but activation of serotonin-producing neurons in the dorsal raphe nucleus persisted. The paper was published in Neuropharmacology.
    Selective serotonin reuptake inhibitors, or SSRIs, are a widely used class of antidepressant medications. They are commonly prescribed to treat depression and some anxiety disorders. SSRIs work by blocking the reabsorption of serotonin, a neurotransmitter involved in regulating mood and other psychological processes, thereby increasing its availability in the brain.
    However, abruptly stopping SSRI treatment can cause withdrawal-like symptoms, including increased anxiety, sleep disturbances, and unusual sensory experiences. These symptoms typically appear within a few days of discontinuation and can persist for several weeks or even longer. Animal studies have shown that stopping SSRI treatment can also produce behavioral changes resembling anxiety, including increased vigilance and avoidance of potentially threatening environments.
    Previous research by the same team found that anxiety-like behavior in mice appeared two days after paroxetine was discontinued but had disappeared by five days, although disturbances in sleep and reduced weight gain lasted longer. Scientists believe that these effects may involve changes in the activity of brain circuits regulating anxiety, particularly those involving serotonin-producing neurons.
    Study author Helen M. Collins of the University of Oxford and colleagues investigated how discontinuing paroxetine affects c-Fos immunoreactivity in a range of brain regions linked to anxiety. The protein c-Fos helps regulate gene expression and is produced in increased amounts in neurons after they become active, which makes it useful as a marker of recent neuronal activity. Researchers can detect this protein using antibodies, a technique known as c-Fos immunoreactivity, to identify neurons that have recently been activated.
    The study was conducted on male mice that were seven weeks old at the start of the study. The mice were housed in groups of three littermates. The researchers studied only males because their previous research did not find evidence that discontinuing paroxetine increases anxiety in female mice.
    Mice were randomly assigned to one of three groups of 12. For 12 days, two groups received daily injections of paroxetine (10 mg/kg) and one group received saline injections. Afterward, the saline group and one paroxetine group continued their treatments for another two or five days, while the third group, the discontinuation group, was switched from paroxetine to saline injections.
    All mice were then tested on an elevated plus maze, a standard test of anxiety-like behavior in rodents. Ninety minutes later, six or seven randomly selected mice from each group were euthanized, and their brains were examined for signs of recent neuronal activity using c-Fos immunoreactivity. The behavioral results from these mice were reported in the team’s earlier paper.
    Two days after paroxetine discontinuation, when the mice showed elevated anxiety-like behavior, neural activity was increased in the dorsal raphe nucleus and the ventral hippocampus compared with mice receiving saline. No such increases were found in other anxiety-related regions the researchers examined, including the median raphe nucleus, prefrontal cortex, amygdala, periaqueductal grey, and paraventricular nucleus of the hypothalamus.
    In the dorsal raphe nucleus, the main source of serotonin for the forebrain, the increased activity occurred in serotonin-producing neurons, including a subgroup of neurons that produce both serotonin and glutamate. The authors suggest that stopping an SSRI may suddenly release serotonin neurons from the inhibition they experience during ongoing treatment, producing a rebound in their activity.
    Five days after discontinuation, serotonin neurons in the dorsal raphe nucleus were still more active, but the mice no longer showed increased anxiety-like behavior. Activity in the ventral hippocampus and in the serotonin-glutamate neurons had also returned to normal by this point. The authors note that activation of serotonin neurons alone may therefore not be sufficient to produce anxiety, while ventral hippocampus activity followed the same time course as the anxiety-like behavior.
    “These findings suggest that, under the current conditions, paroxetine discontinuation is associated with a short-lasting activation of anxiety-promoting circuitry limited to DRN 5-HT neurons [dorsal raphe nucleus neurons that produce serotonin] and the hippocampus. This circuitry may contribute to symptoms such as anxiety that are a feature of SSRI discontinuation syndrome,” the study authors concluded.
    The study contributes to the scientific understanding of brain changes following SSRI discontinuation. However, it should be noted that the study was conducted on mice, not humans, and effects in humans might differ. The study also included only male mice, and the brain analyses involved six or seven mice per group, which may have limited the ability to detect subtle changes in other brain regions. In addition, c-Fos provides only a snapshot of recent neural activity, and the study cannot establish that the observed brain changes caused the anxiety-like behavior.
    The paper, “Increased c-Fos immunoreactivity in anxiety-related brain regions following paroxetine discontinuation,” was authored by Helen M. Collins, L. Sophie Gullino, Cara Fuller, Raquel Pinacho, David M. Bannerman, and Trevor Sharp. 

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    How brain cell networks expand and shrink as cocaine habits form

    November 21, 2026

    College students who spend more time in intense physical activity report slightly fewer depressive symptoms

    November 21, 2026

    What Does Silence Mean in Your Relationships?

    November 21, 2026

    Comments are closed.

    Weather

    Trending

    Kristina Bogic On ‘The Body,’ Anya’s Sexuality, & Season 2

    November 12, 2026

    7 Best Texas Roadhouse Orders for the Money

    November 17, 2026

    7 Old-School Steakhouse Dishes You Rarely See Anymore

    November 17, 2026

    Jensen Huang scandal fuels bipartisan push to block AI chip sales to China

    November 18, 2026

    Subscribe to Updates

    Get the latest creative news from eReadIT about money, health, lifestyle and more.

    loader

    Email Address*

    Name

    eReadIT

    eReadIT enjoys delivering you valuable news that will educate, entertain, and enrich the lives of our readers from around the world and throughout your day. To stay up to date on the latest news check out our site.

    • Local News
    • World
    • Politics
    • Money
    • Crypto
    • Technology
    • Sports
    • Entertainment
    • Game
    • Health
    • Watch
    • Travel
    • Lifestyle
    • Podcasts
    • RSS
    • Contact
    • Privacy Policy
    • Terms & Conditions

    EREADIT LLC
    2400 Herodian Way SE, #220
    Smyrna, Georgia 30080
    Email Us : info@ereadit.com

    Copyright © 2026 EREADIT. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.